AmInvest Research retains Hold for IHH Healthcare


  • Analyst Reports
  • Tuesday, 19 Nov 2019

IHH announced on Bursa Malaysia that a notice of contempt has been issued to Fortis by the Supreme Court of India. This was in relation to its decision to buy back hospital assets from Religare Health Trust (RHT).

KUALA LUMPUR: AmInvestment Research is maintaining its HOLD recommendation on IHH Healthcare with an unchanged fair value of RM5.50 based on discounted cashflow (WACC 8.3%; terminal growth rate 3.5%).

IHH announced on Bursa Malaysia that a notice of contempt has been issued to Fortis by the Supreme Court of India. This was in relation to its decision to buy back hospital assets from Religare Health Trust (RHT).

“We maintain our forecasts for IHH as we believe there will be minimal impact operationally. IHH remains a controlling stakeholder in Fortis with management control. Fortis’ results will continue to be consolidated in IHH’s financial statements, ” the research house said on Tuesday.

The key takeaways from yesterday’s teleconference briefing are as follows:

Firstly, the 31.1% expanded voting share capital of Fortis held by IHH was acquired through preferential allotment, which was completed on Nov 13,2018.

IHH said that the subscription was done in a fair and transparent manner after obtaining the requisite corporate and regulatory approvals and in accordance with all applicable laws.

It was undertaken and completed after Malvinder and Shivinder Singh were no longer in control of Fortis. IHH has not dealt with nor colluded with the Singh brothers or any entities related to or controlled by them in relation to the subscription.

Secondly, in light of the judgment, the Fortis open offer and the Malar open offer will not proceed for the time being but IHH remains committed to proceed once the stay is lifted by the Supreme Court of India. There is no expiry to the mandatory open offer.

“Thirdly, we believe this is slightly negative as the mandatory open offer to acquire up to 26% of the expanded capital of Fortis and up to 26% of Fortis Malar would be suspended. Fortis is also at risk of being held guilty of contempt of court.

“We are unsure if this would lead to penalties, reversal of the acquisition or settlement of the Daiichi Sankyo case as this case is unique and it is dependent on the court’s decision, ” the research house said.

AmInvest Research said the hearing on Feb 3,2020 will be the next opportunity for Fortis to present the facts regarding the contempt proceedings. There is a possibility that judgment will be passed on that day, it said.


Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 7
Cxense type: free
User access status: 3
   

Across The Star Online